Sangamo Therapeutics Q2 2024 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $356.000K Miss $8.260M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics (NASDAQ:SGMO) reported Q2 2024 GAAP EPS of $(0.18), missing the $(0.16) estimate. Sales were $356,000, significantly below the $8.26 million estimate and down 94.79% from the same period last year.
August 06, 2024 | 9:29 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sangamo Therapeutics reported disappointing Q2 2024 results with EPS of $(0.18) missing estimates and sales of $356,000 significantly below expectations. This represents a 94.79% decrease in sales year-over-year.
The significant miss on both EPS and sales, along with a drastic year-over-year decline in sales, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100